Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.
Financial Results:
- Granules India Ltd reported Revenues for Q1FY24 of ₹986.00 Crores down from ₹1,020.00 Crore year on year, a fall of 3.33%.
- Total Expenses for Q1FY24 of ₹920.00 Crores up from ₹858.00 Crores year on year, a rise of 7.23%.
- Consolidated Net Profit of ₹48.00 Crores down 62.5% from ₹128.00 Crores in the same quarter of the previous year.
- The Earnings per Share is ₹1.93, down 62.45% from ₹5.14 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish. *The presented data is automatically generated. It may occasionally generate incorrect information.